Literature DB >> 1675142

Alpha-adrenoceptor subtypes in dog saphenous vein that mediate contraction and inositol phosphate production.

P E Hicks1, M Barras, G Herman, P Mauduit, J M Armstrong, B Rossignol.   

Abstract

1. Studies have been made of the contractile responses to the alpha-adrenoceptor agonists phenylephrine (Phen), cirazoline (Cir) or BHT-920 (BHT) in dog isolated saphenous vein (DSV) rings, using the antagonists yohimbine (Yoh), idazoxan (Idaz), prazosin (Praz), WB-4101 (WB) and nitrendipine or zero Ca2+ medium. 2. Contractile concentration-response curves to Phen or BHT were displaced to the right of controls by Yoh (0.01-3 microM) with mean apparent antagonist dissociation constants (pKBs) of 7.9 and 8.6 respectively. Yoh did not show simple competitive antagonism against either agonist, since the Schild plot slopes were significantly less than unity. Neither the antagonist affinity of Yoh against Phen, nor the slope of the Schild plot was modified in the presence of catecholamine uptake inhibitors, nor in the presence of alpha,beta-methylene ATP, which desensitizes P2-purinoceptors, suggesting that Phen does not release ATP, or noradrenaline to cause contraction in DSV. In the presence of Praz (0.3 microM) the antagonist potency of Yoh (mean pKB 7.4) against Phen was slightly decreased. Yoh had low potency against responses induced by Cir (pKB 6.3). 3. WB (0.001-1.0 microM) was a very potent antagonist of Phen-induced contractions, however, the biphasic Schild plot against Phen could be separated into two affinity sites, a high pKB of 9.3 (equivalent to that obtained using Cir as the agonist; pKB 9.6) and a lower affinity (pKB 8.6). WB showed an even lower antagonist affinity (pKB 7.4) against BHT-induced contractions, suggesting that these effects might be mediated by alpha 2A-adrenoceptors. Praz also appeared to identify two sites using Phen-induced contractions, a high pKB of 8.4 was equivalent to that obtained with Cir (pKB 8.2) and a lower affinity site (pKB 7.7; pA2 7.6; slope 1.1) at which Praz showed competitive antagonism. Higher concentrations of Praz were required to antagonize contractions to BHT (pKB 5.9). 4. Idaz was a weak partial agonist in this tissue with threshold contractile effects at concentrations in excess of 3 microM. Idaz (0.1-1 microM) competitively antagonized the contractile effects of BHT, but showed low antagonist affinity against Phen at these concentrations. 5. Contractions to Phen were slightly antagonized by nitrendipine (1 microM), with a 36% decrease in Emax. Contractions to Phen and Cir were also markedly attenuated in zero calcium medium (with EGTA), but maximum responses of 4.2 +/- 0.1 and 3.6 +/- 0.1 g, could be obtained with these agonists respectively. Only part of the contractile effects to Phen or Cir are therefore due to calcium influx (but L-type channels are not totally implicated), while the contractile effects of BHT were abolished in zero Ca2 + medium. Yoh (0.1 microm) retained its antagonist effects on Phen-induced responses in zero Ca2 + medium. 6. The formation of inositol phosphates (InsPs) in the presence of lithium (10mM) was measured after incubation of intact DSV strips with myo-2-[3H]-inositol. Phen (1-1OO0 microM) and Cir (O.O1-1O microm) induced concentration-dependent increases in total labelled InsP1_3, but BHT showed minimal InsP stimulation. InsPs were recovered after Phen (100,M) stimulation (10min) as labelled InsP1 (71%), InsP2 (25%) and InsP3 (4%). Phen (100 microM)-stimulated InsP1-3 formation was significantly antagonized by Praz (10nM), but was not fully inhibited even after Praz 1 microM. Yoh and Praz (0.1 and 1.0 microM) were equipotent inhibitors of this response, while Idaz (0.3 microM) showed no effects. 7. The receptors in DSV which are stimulated by Phen to cause contraction show characteristics of the alpha lA-adrenoceptor (high pM antagonist affinity for WB-4101 and extracellular calcium sensitivity) and the alpha lB-adrenoceptor (contraction in calcium-free medium, increase in InsP and low nm antagonist affinity of WB). The paradoxical results obtained with Yoh (potent antagonist effects on Phen-stimulated PI and pKB 7.9 on contraction) and Praz (low affinity competitive antagonist of Phen-induced contraction, pKB 7.7 and failure to inhibit completely the PI response at 1 microM), cannot fully exclude an alpha 2B-subtype characterization of these responses. These pharmacological differences suggest that the adrenoceptor involved in the contractile and in particular the second messenger effects of Phen in DSV is not typically an alpha lB-adrenoceptor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675142      PMCID: PMC1917904          DOI: 10.1111/j.1476-5381.1991.tb12146.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  63 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor.

Authors:  S Cotecchia; D A Schwinn; R R Randall; R J Lefkowitz; M G Caron; B K Kobilka
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

3.  What do antagonists tell us about alpha-adrenoceptors?

Authors:  G M Drew
Journal:  Clin Sci (Lond)       Date:  1985       Impact factor: 6.124

Review 4.  Subtypes of alpha 2-adrenoceptors: pharmacological and molecular biological evidence converge.

Authors:  D B Bylund
Journal:  Trends Pharmacol Sci       Date:  1988-10       Impact factor: 14.819

5.  Role of extracellular calcium in contractions produced by activation of postsynaptic alpha-2 adrenoceptors in the canine saphenous vein.

Authors:  K F Jim; W D Matthews
Journal:  J Pharmacol Exp Ther       Date:  1985-07       Impact factor: 4.030

6.  Activation of alpha 1-adrenoceptors increases [3H]inositol metabolism in rat vas deferens and caudal artery.

Authors:  A W Fox; P W Abel; K P Minneman
Journal:  Eur J Pharmacol       Date:  1985-10-08       Impact factor: 4.432

7.  Nimodipine and inhibition of alpha adrenergic activation of the isolated canine saphenous vein.

Authors:  J P Cooke; T J Rimele; N A Flavahan; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1985-09       Impact factor: 4.030

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Comparison of alpha 1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB 4101.

Authors:  K P Minneman; C Han; P W Abel
Journal:  Mol Pharmacol       Date:  1988-05       Impact factor: 4.436

10.  Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype.

Authors:  D B Bylund; C Ray-Prenger; T J Murphy
Journal:  J Pharmacol Exp Ther       Date:  1988-05       Impact factor: 4.030

View more
  5 in total

1.  Investigations of the subtype of alpha 2-adrenoceptor mediating contractions of the human saphenous vein.

Authors:  K Smith; S Connaughton; J R Docherty
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

2.  The pharmacology of RS-15385-197, a potent and selective alpha 2-adrenoceptor antagonist.

Authors:  C M Brown; A C MacKinnon; W S Redfern; P E Hicks; A T Kilpatrick; C Small; M Ramcharan; R U Clague; R D Clark; C B MacFarlane
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

3.  Interactions of chloroethylclonidine with rauwolscine- and prazosin-sensitive adrenoceptors in dog saphenous vein.

Authors:  A M Low; D M Bowdish; T R Prashad; V Gaspar
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

4.  Unusual alpha-adrenoceptor subtype in canine saphenous vein: comparison to mesenteric vein.

Authors:  E E Daniel; A M Low; V Gaspar; H Lu-Chao; J Green; J Akrong; S Duerksen; C Soyka; C K Chen; J Boyd; C Y Kwan
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

5.  Chloroethylclonidine irreversibly activates postjunctional alpha 2-adrenoceptors in the dog saphenous vein.

Authors:  J P Nunes; S Guimarães
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-09       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.